You are here

Structural & Congenital Heart Disease

 

Symptoms of depression are widespread among elderly patients undergoing aortic valve replacement (AVR) surgery, and the condition is associated with as much as a threefold increase in mortality risk a year after the procedure, researchers reported in JAMA Cardiology this week.

Next-day discharge after minimalist transcatheter aortic valve replacement (TAVR) was safe for patients who didn’t experience perioperative complications and was linked to better one-year outcomes versus patients discharged later, according to a single-center study published in JACC: Cardiovascular Interventions.

The American Heart Association (AHA) and American College of Cardiology (ACC) rolled out new guidelines for managing valvular heart disease (VHD) in 2017, marking the second overhaul of VHD recommendations in three years—a move attributable to “extensive new data” that have shaped the way clinicians treat valve disease.

A larger valve option and more appropriate valve sizing using preprocedural imaging may eliminate the previously reported survival disparity between men and women undergoing transcatheter aortic valve replacement (TAVR), a new study in JACC: Cardiovascular Interventions suggests.

Procedures to replace or repair patients’ tricuspid valves (TVs) remain rare but have increased in recent years, according to a study in the Journal of the American College of Cardiology. But despite this increased volume, in-hospital mortality has remained steady at 8.8 percent.

 

Recent Headlines

JACC: Bioprosthetic aortic valves have more failure, reoperation Patients who have undergone an aortic valve replacement with either a bioprosthetic (BP) or mechanical valve display the same rates of adverse events, as well as similar survival rates after 13 years, but those who received a BP valve have more incidence of valve failure and reoperation, according to an eight-year study in the Nov. 17 edition of the Journal of the American College of Cardiology.
Abbott completes $410M purchase of mitral valve repair developer Abbott has completed its acquisition of Evalve, a developer of devices for minimally invasive repair of mitral valves.
JACC: Medtronics transcatheter pulmonary valve shows promise Implantation of the Melody transcatheter pulmonary valve (Medtronic, Minneapolis) for right ventricular outflow tract conduit dysfunction can be performed by experienced operators at multiple centers, appears safe, and has encouraging acute and short-term outcomes, according to a study in the Oct. 27 issue of the Journal of the American College of Cardiology.
Edwards to open new manufacturing, R&D facility in Utah Edwards Lifesciences, a developer of heart valves and hemodynamic monitoring products, is developing a new manufacturing facility in Draper, Utah, which will enable the company to expand its manufacturing and R&D capability.
TCT: Abbot CMO Simonton touts DES results, talks valve replacement The long-awaited SPRIT IV one-year results, presented at the recent Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francicso, for Abbotts Xience V drug-eluting stent (DES) over Boston Scientifics Taxus DES found a stent thrombosis rate of 0.29 percent, which surprised even Chuck Simonton, Abbotts chief medical officer.
TCT: Aortic valve implants have very low complication rates up to one year SAN FRANCISCOMid-term valve-related complications are exceptionally low, and the gradient release after transcatheter aortic valve prosthesis implantation is stable up to one year of follow up, according to a study presented this week at the 2009 Transcatheter Cardiovascular Therapeutics meeting.
TCT: Transcatheter valve therapy explodes, standardization sought SAN FRANSISCOAn estimated 10,000 transcatheter heart valves have been implanted in patients with critical valvular aortic stenosis, and the researchers, who have their eyes on U.S. approval, are now seeking to standardize the techniques and trial expectations, according to a presentation by Martin B. Leon, MD, at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) symposium.

Pages